These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31009912)

  • 1. Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.
    Ammazzalorso A; Maccallini C; Amoia P; Amoroso R
    Eur J Med Chem; 2019 Jul; 173():261-273. PubMed ID: 31009912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
    Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
    ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective PPARγ modulators for Type 2 diabetes treatment: how far have we come and what does the future hold?
    Lavecchia A; Cerchia C
    Future Med Chem; 2018 Apr; 10(7):703-705. PubMed ID: 29671628
    [No Abstract]   [Full Text] [Related]  

  • 4. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones as antidiabetic agents: A critical review.
    Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
    Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
    Savkur RS; Miller AR
    Expert Opin Investig Drugs; 2006 Jul; 15(7):763-78. PubMed ID: 16787140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
    Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
    Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
    Sæther T; Paulsen SM; Tungen JE; Vik A; Aursnes M; Holen T; Hansen TV; Nebb HI
    Eur J Med Chem; 2018 Jul; 155():736-753. PubMed ID: 29940464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
    Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
    Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.
    Choung W; Yang D; Kim H; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim WS; Kim KH; Chin J; Jung K; Lee G; Hong E; Jang TH; Joo J; Hwang H; Myung J; Kim SH
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2275-2282. PubMed ID: 31253533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activity.
    Guasch L; Sala E; Mulero M; Valls C; Salvadó MJ; Pujadas G; Garcia-Vallvé S
    PLoS One; 2013; 8(2):e55889. PubMed ID: 23405231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome.
    Ramachandran U; Kumar R; Mittal A
    Mini Rev Med Chem; 2006 May; 6(5):563-73. PubMed ID: 16719831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1617-22. PubMed ID: 18255290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.